enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Global Initiative for Chronic Obstructive Lung Disease

   en.wikipedia.org/wiki/Global_Initiative_for...

   [1] [2] They have organized the annual awareness day, World COPD Day, every November since 2002. [3] This organization issues recommendations for the treatment of chronic obstructive pulmonary disease and related medical conditions. GOLD issued its first formal recommendations in 2001. [2]

3. World Chronic Obstructive Pulmonary Disease Day - Wikipedia

   en.wikipedia.org/wiki/World_Chronic_Obstructive...

   The inaugural World COPD Day took place on November 14, 2002, initiated by GOLD in collaboration with health professionals and COPD patient groups. Since then, it has become a crucial event in the global fight against COPD. [5] World COPD Day is observed annually on the third Wednesday of November.

4. Chronic obstructive pulmonary disease - Wikipedia

   en.wikipedia.org/wiki/Chronic_obstructive...

   Chronic obstructive pulmonary disease (COPD) is a type of progressive lung disease characterized by chronic respiratory symptoms and airflow limitation. [8] GOLD 2024 defined COPD as a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea or shortness of breath, cough, sputum production or exacerbations) due to abnormalities of the airways (bronchitis ...

5. A Guide for Living With COPD - AOL

   www.aol.com/lifestyle/guide-living-copd...

   For premium support please call: 800-290-4726 more ways to reach us

6. GSK to cap out-of-pocket inhaler costs in US - AOL

   www.aol.com/news/gsk-cap-pocket-inhaler-costs...

   The cost cap would apply to all of its asthma and chronic obstructive pulmonary disease (COPD) medicines, including Advair Diskus, Advair HFA, and Trelegy Ellipta, and would apply to patients ...

7. Fluticasone furoate/umeclidinium bromide/vilanterol - Wikipedia

   en.wikipedia.org/wiki/Fluticasone_furoate/...

   The combination fluticasone furoate/umeclidinium bromide/vilanterol product is approved by the US Food and Drug Administration with an indication for the maintenance treatment of a chronic lung problem called chronic obstructive pulmonary disease (COPD) in adults who (1) have already tried fluticasone furoate/vilanterol (brand name Breo Ellipta) but are still experiencing symptoms of airway ...